Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference
Rhea-AI Summary
Volition (NYSE AMERICAN: VNRX) presented an ELCC 2026 abstract showing that preoperative H3K27Me3-nucleosome levels measured by Nu.Q Cancer assays stratify non-small cell lung cancer prognosis.
High H3K27Me3 levels predicted poorer recurrence-free and overall survival; low levels indicated better outcomes and potential micro-metastatic detection, with poster data and prior studies cited.
Positive
- Poster presented at ELCC Mar 26, 2026
- Interim analysis referenced up to 832 patients in prior ELCC 2025 poster
Negative
- Findings described as interim; not yet definitive for widescale clinical adoption
- Company states it is only on the path to first clinical use, implying implementation is pending
Key Figures
Market Reality Check
Peers on Argus
VNRX was down 4.87% with heavy volume. Among close peers, ICCM fell 5.16%, LUNG 1.52%, and TELA 9.32%, while CTSO rose 3.79%. Momentum scanner shows ICCM sharply down (-26.87%) and CTSO up (+5.01%), highlighting mixed moves rather than a uniform sector trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 25 | Cancer detection data | Positive | -4.9% | Blinded validation showing ~95% early-stage cancer detection and strong sensitivity/specificity. |
| Mar 18 | Liquid biopsy breakthrough | Positive | +5.3% | Reported >99% pure ctDNA isolation with Capture-Seq and strong blinded cohort detection. |
| Mar 06 | Vet test automation | Positive | +0.7% | First automated Nu.Q® Vet Cancer Test launch with Fujifilm Vet Systems in Japan. |
| Feb 25 | Commercial momentum update | Positive | +25.6% | Update on Capture-Seq, lung cancer reimbursement, sepsis program, and CE-marked Nu.Q® NETs. |
| Feb 10 | Distribution agreement | Positive | -3.0% | New Nu.Q® Discover distributor in Japan and discussion of ~$1B addressable market. |
Recent news has generally been positive technologically and commercially, but price reactions have been mixed, with three aligned gains and two notable divergences where positive news coincided with declines.
Over the past few months, Volition has reported multiple advances across its portfolio. On Feb 10, it expanded Nu.Q® Discover distribution in Japan with strong 2025 growth commentary yet saw a -3.05% move. A Feb 25 update on commercial momentum and multi-pillar execution coincided with a strong +25.62% reaction. In March, successive liquid biopsy breakthroughs, including >99% purity ctDNA isolation and ~95% early-stage detection, drew both positive (+5.26%) and negative (-4.87%) responses. Today’s ELCC lung cancer stratification data fits this ongoing narrative of clinical validation in liquid biopsy and Nu.Q® applications.
Regulatory & Risk Context
An effective S-3 dated 2026-02-09 registers 17,968,090 common shares for resale by existing investors, including shares from private placements and from a secured convertible note and warrants. The company receives no proceeds from these resales, but the filing notes that larger selling holders and warrant-related shares could create meaningful share overhang if sizable blocks are sold into the market.
Market Pulse Summary
This announcement highlights further validation of Volition’s Nu.Q® Cancer technology, with H3K27Me3-nucleosome levels used for prognostic stratification in non-small cell lung cancer and potential identification of micro-metastatic disease. It builds on prior references involving cohorts of up to 832 patients and multiple ELCC presentations, reinforcing a focus on risk stratification and treatment decision support. Investors may watch for progression from conference data into routine clinical use and any subsequent commercial agreements or reimbursement milestones.
Key Terms
liquid biopsy medical
non small cell lung cancer medical
prognostic biomarker medical
circulating tumor dna medical
AI-generated analysis. Not financial advice.
Poster 244P : Preoperative Nucleosome Liquid Biopsy for Prognostic Stratification in Lung Cancer With Treatment Correlation1
Joint lead author Dr. Pei-Hsing Chen, Assistant Professor, Surgical Department, National Taiwan University Hospital,
"A key finding from this study was that measuring preoperative H3K27Me3-nucleosomes using Volition's simple blood test allows us to identify which Non Small Cell Lung Cancer patients are most likely to benefit from closer follow-ups or secondary cancer treatment.
"While high H3K27Me3-nucleosome levels predicted poorer recurrence-free and overall survival outcomes, low H3K27me3 levels indicated significantly better outcomes.
"Volition's Nu.Q® H3K27Me3-nucleosome levels may also help identify micro-metastatic disease and support systemic treatment decision-making in high-risk patients.
"The Nu.Q® Cancer technology supports a practical approach to empower clinicians to make more informed treatment decisions and provides valuable new monitoring capabilities throughout the patient journey."
Dr Andrew Retter, Medical Consultant, Volition, said:
"Nu.Q® Cancer represents a significant advancement in lung cancer patient management, offering clinicians an additional tool to enhance precision in treatment selection and monitoring.
"Research conducted by our long-term collaborators in
"By enriching clinical prognostication, Nu.Q® Cancer helps identify the most appropriate treatment pathway for an individual patient, supporting efforts to improve overall survival and deliver patient-centred care.
"We are now on the path to the first use of Nu.Q® in clinical practice, an exciting prospect which is core to Volition's mission, using our tests to help save lives"
- Pei-Hsing Chen et al "Nucleosome Liquid Biopsy for Prognostic Stratification in Lung Cancer With Treatment Correlation" Poster 244P ELCC 2026
- Grolleau E, et al. Circulating H3K27 Methylated Nucleosome Plasma Concentration: Synergistic Information with Circulating Tumor DNA Molecular Profiling. Biomolecules. 2023;13(8):1255. https://doi.org/10.3390/biom13081255
- Couraud S, et al Baseline values of circulating nucleosomes in Lung Cancer: NUCLEO-LUNG study. ELCC 2024 Poster
- Marie Piecyk et al, "H3K27Me3-nucleosome is a strong prognostic biomarker in Non-Small Cell Lung Cancer: interim results from the analysis of up to 832 patients at baseline" Poster 395 ELCC 2025
About Volition
About Volition: Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.
Volition's research and development activities are centered in
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
Media Enquiries: Louise Batchelor, Volition, mediarelations@volition.com +44 (0)7557 774620
Safe Harbor Statement
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, Volition's expectations regarding future publications, Volition's success in securing licensing and/or distribution agreements with third parties for its products, and Volition's expectations regarding the terms of such agreements. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of
View original content:https://www.prnewswire.com/news-releases/volition-announces-abstract-demonstrating-risk-stratification-in-lung-cancer-presented-at-the-european-lung-cancer-conference-302726071.html
SOURCE VolitionRx Limited
FAQ
What did Volition (VNRX) present at ELCC on March 26, 2026 regarding lung cancer?
How do Nu.Q Cancer H3K27Me3 levels affect prognosis for NSCLC patients in the ELCC poster?
Does the ELCC 2026 data mean Nu.Q assays are in routine clinical use for lung cancer now?
What evidence size supports Volition's H3K27Me3 claims for lung cancer prognosis?
How might Nu.Q H3K27Me3 testing change treatment decisions for NSCLC patients (VNRX)?
